Prosecution Insights
Last updated: November 04, 2026
Application No. 18/640,024

STARCH-INDOLE-ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Non-Final OA §102§112
Filed
Apr 19, 2024
Priority
Oct 19, 2021 — CN 202111213344.7 +1 more
Examiner
BERRY, LAYLA D
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shandong Shanwei Immunotech Co. Ltd.
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
963 granted / 1459 resolved
+6.0% vs TC avg
Moderate +9% lift
Without
With
+9.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
49 currently pending
Career history
1508
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
34.1%
-5.9% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1459 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . CONTINUING DATA This application is a CIP of PCT/CN2022/125134 10/13/2022 FOREIGN APPLICATIONS CHINA 202111213344.7 10/19/2021 Applicant's election with traverse of Group I, claims 1-7 in the reply filed on September 30, 2026 is acknowledged. The traversal is on the ground(s) that the examiner has not established a serious search and/or examination burden. This is not found persuasive because the groups require different search queries due to mutually exclusive characteristics, the groups are classified differently, and the groups are likely to raise different non-prior art issues because Group III is drawn to a “use.” See MPEP 808.02 for a discussion of establishing burden. The requirement is still deemed proper and is therefore made FINAL. Claims 8-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on September 30, 2026. Applicant is reminded that if claim 1 is found allowable, claims 8-16 will be eligible for rejoinder provided that they recite all the limitations of an allowable claim. Priority This application is a CIP of PCT/CN2022/125134, which is not in English. This application claims foreign priority to CHINA 202111213344.7, which is not in English. An English translation will be required to perfect the claim for benefit of priority because an intervening reference has been found. A certified copy of PCT/CN2022/125134 is not found in the application file, with or without an English translation. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 6-7 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 6-7 depend from claim 5, which depends from claim 1. Claims 6 and 7 recite the substitution degrees of each starch derivative, respectively. Claims 6 and 7 do not further limit claim 5 because claim 5 depends from claim 1, which already requires the same substitution degree recited in claims 6-7. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-7 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Song (Carbohydrate Polymers Volume 302, 15 February 2023, 120425, cited on IDS). Song was available online December 1, 2022. Applicant cannot rely upon the certified copy of the foreign priority application to overcome this rejection because a translation of said application has not been made of record in accordance with 37 CFR 1.55. When an English language translation of a non-English language foreign application is required, the translation must be that of the certified copy (of the foreign application as filed) submitted together with a statement that the translation of the certified copy is accurate. See MPEP §§ 215 and 216. Song teaches the compound HAMSIAA, shown in Figure 1. PNG media_image1.png 233 434 media_image1.png Greyscale HAMS is HI-MAIZE 260, amylose content of 63.7% (high amylose). Section 2.1. The DS was 0.065, 0.12, 0.19, 0.32, 0.37, or 0.49. Table 2. IAA is indole-3-acetic acid. See abstract. The composition was prepared through an esterification reaction between the carboxyl group of IAA and the hydroxyl group of HAMS, using EDCI as the coupling reagent and 1-methylimidazole as the base and catalyst. Section 2.2. Claim(s) 1-7 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Cai (Carbohydrate Research 345 (2010) 922-928, cited on IDS). Cai teaches a conjugate of indomethacin and amylose, synthesized using DCC and DMAP. See abstract. Indomethacin is an indoleacetic acid as shown on page 923. PNG media_image2.png 178 416 media_image2.png Greyscale Amylose was from potatoes. Section 4.1. The amount of amylose used is 1.0 g and five samples using indomethacin at amounts of 0.22, 0.44, 0.88, 1.32, and 1.76 g are manufactured. Sections 4.1 and 4.2. The glucose repeating units in amylose have a molecular weight of 162 g/mol and the amount of 1.0 g used by Cai corresponds to 6.2 mmol. The molecular weight of indomethacin is 358 g/mol and the used amounts correspond to 0.6, 1.2, 2.4, 3.6, and 4.8 mmol, which corresponds to 0.1, 0.2, 0.4, 0.6, and 0.8 equivalents of indole acid. The equivalents of indole acid employed are the same as or very close to those used in Example 1 (0.1, 0.2, 0.33, 0.4, 0.6, 1.0) of the current application, which uses the same type of conjugation method. Thus, the degree of substitution of amylose with indomethacin in Cai’s examples necessarily falls within the range recited in current claim 1. The claimed conjugate “comprises” indoleacetic acid derivatized starch, which is open language. Cai’s indomethacin comprises an indoleacetic acid structure. The current claims are product-by-process claims, and patentability is based on the product itself. Amylose from high-amylose starch is not structurally different from amylose from other starches, so the structure of the derivative is the same. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA D BERRY whose telephone number is (571)272-9572. The examiner can normally be reached 7:00-3:00 CST, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAYLA D BERRY/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Apr 19, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779771
CELLULOSE-BASED FILAMENTS, FILMS AND 3D OBJECTS AND METHODS OF MANUFACTURE THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12781027
Molding Material
2y 7m to grant Granted Nov 03, 2026
Patent 12780862
Methyl Fructoside Polyether Amine, Preparation Method Therefor and Use Thereof
2y 5m to grant Granted Nov 03, 2026
Patent 12774298
AMORPHOUS FORM OF 5-BROMOPYRIDIN-3-YL 3-DEOXY-3-[4-(3,4,5-TRIFLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL]-1-THIO-ALPHA-D-GALACTOPYRANOSIDE
5y 4m to grant Granted Oct 27, 2026
Patent 12765551
ANTIMICROBIAL COMPOSITION COMPRISING A MODIFIED ALKYL GLYCOSIDE AND AN ALKANEDIOL
3y 0m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
75%
With Interview (+9.1%)
2y 9m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1459 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month